Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Net Cash Flow: 2023-2025

Historic Net Cash Flow for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $21.8 million.

  • Contineum Therapeutics' Net Cash Flow rose 160.13% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 92.55%. This contributed to the annual value of $6.4 million for FY2024, which is 35.55% down from last year.
  • Latest data reveals that Contineum Therapeutics reported Net Cash Flow of $21.8 million as of Q3 2025, which was up 1,395.91% from -$1.7 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Net Cash Flow peaked at $61.0 million during Q2 2024, and registered a low of -$36.3 million during Q3 2024.
  • In the last 3 years, Contineum Therapeutics' Net Cash Flow had a median value of $527,000 in 2025 and averaged $3.4 million.
  • In the last 5 years, Contineum Therapeutics' Net Cash Flow tumbled by 849.77% in 2024 and then skyrocketed by 160.13% in 2025.
  • Contineum Therapeutics' Net Cash Flow (Quarterly) stood at -$2.0 million in 2023, then plummeted by 849.77% to -$18.9 million in 2024, then surged by 160.13% to $21.8 million in 2025.
  • Its last three reported values are $21.8 million in Q3 2025, -$1.7 million for Q2 2025, and $527,000 during Q1 2025.